BBIO – bridgebio pharma, inc. (US:NASDAQ)
Stock Stats
News
11/19
02:49 pm
bbio
Low
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market [Yahoo! Finance]
11/19
06:25 am
bbio
Low
The Consensus EPS Estimates For BridgeBio Pharma, Inc. (NASDAQ:BBIO) Just Fell Dramatically [Yahoo! Finance]
11/18
11:28 am
bbio
Medium
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months [Yahoo! Finance]
11/18
11:15 am
bbio
Low
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
11/18
05:31 am
bbio
Medium
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia [Yahoo! Finance]
11/12/2024
07:30 am
BBIO
-5.7%
BEAT
8/1/2024
07:30 am
BBIO
0.5%
BEAT
5/2/2024
07:30 am
BBIO
-0.1%
BEAT
2/22/2024
07:30 am
BBIO
-0.9%
MISS
11/15
12:10 pm
Maintains
Sector Outperform
Sector Outperform
Scotiabank
Low
2.1%
11/15
12:10 pm
Maintains
Sector Outperform
Sector Outperform
Scotiabank
Low
2.1%
10/25
08:37 am
Reiterates
Buy
Buy
HC Wainwright
Low
-1.4%
10/17
10:41 am
Maintains
Outperform
Outperform
Leerink Partners
Low
0.3%
10/16
10:00 am
Initiates
Sector Outperform
Scotiabank
Low
0.1%
11/20
08:01 pm
bbio
Low
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: Kumar Neil
11/20
07:58 pm
bbio
Low
Form 4 BridgeBio Pharma, Inc. For: Nov 19 Filed by: STEPHENSON BRIAN C
11/19
06:16 pm
bbio
Medium
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Kumar Neil
11/19
06:14 pm
bbio
Medium
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: Trimarchi Thomas
11/19
06:06 pm
bbio
Low
Form 4 BridgeBio Pharma, Inc. For: Nov 16 Filed by: STEPHENSON BRIAN C
Show more
Top News Gainers
3/19 BridgeBio Pharma (NASDAQ: BBIO) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 26.9%
12/19 BridgeBio Pharma, Inc. to Present at Upcoming Investor Conference 13.7%
4/3 Form 4 BridgeBio Pharma, Inc. For: Apr 01 Filed by: STEPHENSON BRIAN C 12.4%
10/30 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 11.6%
11/7 Q3/2019 9/30/2019 EPS -0.510 ZacksConsensus N/A ActVsEst N/A - N/A 10.8%
7/22 BridgeBio Pharma (NASDAQ: BBIO) is now covered by analysts at Jefferies Financial Group Inc. They set a "buy" rating on the stock. 10.3%
4/7 Form 4 BridgeBio Pharma, Inc. For: Apr 03 Filed by: HOMCY CHARLES J 10.3%
12/9 BridgeBio Pharma, Inc. Appoints Eli Wallace as Chief Scientific Officer in Residence for Oncology Programs 10.2%
12/18 BridgeBio Pharma’s Origin Biosciences Enters Partnership With Medison to Commercialize BBP-870 in Israel for MoCD Type A 10.1%
11/19 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. 9.9%
Top News Decliners
3/12 BridgeBio Pharma’s QED Therapeutics Announces Dosing of First Patients in Phase 3 and Phase 2 Clinical Trials of Infigratinib in Tumors with FGFR Genetic Alterations -16.6%
12/26 Form 8-K BridgeBio Pharma, Inc. For: Nov 07 -14.3%
6/26 Form S-1MEF BridgeBio Pharma, Inc. -10.0%
2/21 BridgeBio Pharma And Eidos Therapeutics To Present At Upcoming Investor Conferences -8.0%
9/24 Ivy Brain Tumor Center and BridgeBio Subsidiary QED Therapeutics Announce Collaboration to Advance Cancer Research and Treatment Options -7.8%
1/10 BridgeBio Pharma’s Gene Therapy Subsidiaries Enter Strategic Partnership with Catalent for Dedicated Gene Therapy Development and Manufacturing Capacity -7.6%
4/7 Form SEC STAFF LETTER BridgeBio Pharma, Inc. -5.8%
12/24 BridgeBio Pharma (NASDAQ: BBIO) was upgraded by analysts at Zacks Investment Research from a "sell" rating to a "hold" rating. -5.5%
12/31 Form 4 BridgeBio Pharma, Inc. For: Dec 27 Filed by: MCCORMICK FRANK -5.2%
3/3 BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) -4.7%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3